Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;35(4):1943-1949.
doi: 10.1111/jvim.16162. Epub 2021 May 17.

Effect of doxepin on quality of life in Labradors with laryngeal paralysis: A double-blinded, randomized, placebo-controlled trial

Mark Rishniw  1 , Jill Sammarco  2 , Eric N Glass  2 , Brittany Cerroni  3
Affiliations

Effect of doxepin on quality of life in Labradors with laryngeal paralysis: A double-blinded, randomized, placebo-controlled trial

Mark Rishniw et al. J Vet Intern Med. 2021 Jul.

Abstract

Background: Laryngeal paralysis commonly affects older Labrador retrievers. Currently, dogs with severe disease require surgical intervention, most commonly arytenoid lateralization. Anecdotally, doxepin has been proposed to help dogs with laryngeal paralysis.

Hypothesis: Doxepin will improve quality of life measures assessed by owners of Labrador retrievers with laryngeal paralysis not requiring emergency surgery.

Animals: Twenty-two Labrador retrievers with laryngeal paralysis.

Methods: Dogs were randomized to receive doxepin (3-5 mg/kg q12h PO) or placebo for 28 days. Owners completed quality-of-life assessments before and after completing the study. Data were compared between groups using Rank-Sum tests or Fisher's exact tests.

Results: The 2 groups of dogs did not differ at baseline except for owner-perceived degree of ataxia (owners of dogs receiving doxepin considered them more ataxic than owners of dogs receiving placebo). After 28 days, owner-assessed quality of life measures did not differ between dogs receiving doxepin or placebo (dogs worsening: doxepin = 2, placebo = 1; dogs unchanged: doxepin = 6, placebo = 7; dogs improved: doxepin = 4, placebo = 2; P = .84). Dogs receiving placebo had a greater improvement in client-assessed overall health than dogs receiving doxepin (mean ranks: doxepin = 4.36, placebo = 6.64; P = .04). The study was terminated at this interim analysis.

Conclusions and clinical importance: Doxepin did not appear to improve any measures of owner-assessed quality of life in Labrador retrievers with laryngeal paralysis.

Keywords: arytenoid intervention; dogs.

PubMed Disclaimer

Conflict of interest statement

Authors declare no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Study flowchart
See this image and copyright information in PMC

References

    1. Snelling SR, Edwards GA. A retrospective study of unilateral arytenoid lateralisation in the treatment of laryngeal paralysis in 100 dogs (1992–2000). Australian Veterinary Journal. 2003;81(8):464‐468. 10.1111/j.1751-0813.2003.tb13361.x. - DOI - PubMed
    1. Hammel SP, Hottinger HA, Novo RE. Postoperative results of unilateral arytenoid lateralization for treatment of idiopathic laryngeal paralysis in dogs: 39 cases (1996‐2002). J Am Vet Med Assoc. 2006;228:1215‐1220. - PubMed
    1. Schofield DM, Norris J, Sadanaga KK. Bilateral thyroarytenoid cartilage lateralization and vocal fold excision with mucosoplasty for treatment of idiopathic laryngeal paralysis: 67 dogs (1998‐2005). Vet Surg. 2007;36:519‐525. - PubMed
    1. MacPhail CM, Monnet E. Outcome of and postoperative complications in dogs undergoing surgical treatment of laryngeal paralysis: 140 cases (1985‐1998). J Am Vet Med Assoc. 2001;218(12):1949‐1956. - PubMed
    1. Gaber CE, Amis TC, LeCouteur RA. Laryngeal paralysis in dogs: a review of 23 cases. J Am Vet Med Assoc. 1985;186:377‐380. - PubMed

Publication types

LinkOut - more resources